Cellular prion protein as a therapeutic target in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 38, Issue 2, 2014, Pages 227-244

  Laurén, Juha ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alzheimer's disease; amyloid peptides; c fyn protein; prion protein

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; GLUTAMATE RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ICSM 18; ICSM 35; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METABOTROPIC RECEPTOR; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; OLIGOMER; PRION PROTEIN; PRION PROTEIN ANTIBODY; PROTEIN KINASE FYN; SYNAPTOPHYSIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANTIGEN BINDING; BETA SHEET; BINDING ASSAY; BINDING SITE; BLOOD BRAIN BARRIER; BOVINE SPONGIFORM ENCEPHALOPATHY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL MEMBRANE; CHOLINERGIC NERVE CELL; CONDUCTANCE; CONFORMATIONAL TRANSITION; CREUTZFELDT JAKOB DISEASE; DENDRITIC SPINE; DNA SEQUENCE; GEL ELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; GENE DELETION; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN GENETICS; IC 50; IMMUNOREACTIVITY; IMMUNOTHERAPY; INTERNALIZATION; LEARNING; LIGAND BINDING; LONG TERM POTENTIATION; MEMORY; META ANALYSIS (TOPIC); MOLECULAR CLONING; MOLECULAR INTERACTION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; TRANSCYTOSIS; TRANSMISSION ELECTRON MICROSCOPY;

ALZHEIMER'S DISEASE; AMYLOID-Β PEPTIDES; C-FYN PROTEIN; PRION PROTEIN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HIPPOCAMPUS; HUMANS; MICE; PRPC PROTEINS; SYNAPSES;

EID: 84889570015     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130950     Document Type: Review

References (107)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, JonesE(2011) Alzheimer's disease. Lancet 377, 1019-1031.
2. Alzheimer's, Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
3. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397. (Pubitemid 351665469)
4. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
5. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
6. Klein WL (2013) Synaptotoxic amyloid-oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease J Alzheimers Dis 33 (Suppl 1), S49-S65.
7. Lauŕen J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.
8. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A (2010) Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2, 306-314.
9. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, ForloniG(2010) Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 107, 2295-2300.
10. Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G, Borsello T, Gobbi M, Harris DA (2013) An N-terminal fragment of the prion protein binds to amyloid-oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 288, 7857-7866.
11. Resenberger UK, Harmeier A, Woerner AC, Goodman JL, M̈uller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FU, Multhaup G,Winklhofer KF, Tatzelt J (2011) The cellular prion protein mediates neurotoxic signalling of-sheet-rich conformers independent of prion replication. EMBO J 30, 2057-2070.
12. Nieznanski K, Choi J-K, Chen S, Surewicz K, Surewicz WK(2012) Soluble prion protein inhibits amyloid-beta (A) fibrillization and toxicity. J Biol Chem 287, 33104-33108.
13. Zou W-Q, Xiao X, Yuan J, Puoti G, Fujioka H, Wang X, Richardson S, Zhou X, Zou R, Li S, Zhu X, McGeer PL, McGeehan J, Kneale G, Rincon-Limas DE, Fernandez-Funez P, Lee H, Smith MA, Petersen RB, Guo J-P (2011) Amyloid-beta 42 interacts mainly with insoluble prion protein in the alzheimer brain. J Biol Chem 286, 15095-15105.
14. Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH (2013) The cellular prion protein traps Alzheimer'sAin an oligomeric form and disassembles amyloid fibers. FASEB J 27, 1847-1858.
15. Chen S,Yadav SP, SurewiczWK(2010) Interaction between human prion protein and amyloid-beta (Abeta) oligomers: Role of N-terminal residues. J Biol Chem 285, 26377-26383.
16. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, RowanMJ,Walsh DM, Collinge J (2011) Interaction between prion protein and toxic amyloidassemblies can be therapeutically targeted at multiple sites. Nat Commun 2, 336.
17. Rushworth JV, Griffiths HH, Watt NT, Hooper NM (2013) Prion protein-mediated toxicity of amyloid-oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem 288, 8935-8951.
18. Guillot-Sestier M-V, Sunyach C, Ferreira ST,Marzolo M-P, Bauer C, Thevenet A, Checler F (2012) Alpha-secretasederived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid beta (Abeta)-associated cell death. J Biol Chem 287, 5021-5032.
19. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Ẅuthrich K (1996) NMR structure of the mouse prion protein domain PrP(121-231). Nature 382, 180-182. (Pubitemid 26242887)
20. Altmeppen HC, Prox J, Puig B, Dohler F, Falker C, Krasemann S, Glatzel M (2013) Roles of endoproteolytic-cleavage and shedding of the prion protein in neurodegeneration. FEBS J, doi: 10.1111/febs.12196
21. Benilova I, Karran E, De Strooper B (2012) The toxic Aoligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15, 349-357.
22. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235.
23. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesńe SE (2012) The complex PrP(c)-Fyn couples human oligomericAwith pathological tau changes in Alzheimer's disease. J Neurosci 32, 16857-16871.
24. Barry AE, Klyubin I,McDonald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ (2011) Alzheimer's disease brain-derived amyloid-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 31, 7259-7263.
25. Bate C, Williams A (2011) Amyloid-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem 286, 37955-37963.
26. Portelius E, Olsson M, Brinkmalm G, R̈uetschi U, Mattsson N, Andreasson U, Gobom J, Brinkmalm A, Ḧoltẗa M, Blennow K, Zetterberg H (2013) Mass spectrometric characterization of amyloid-species in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis 33, 85-93.
27. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18.
28. Costanzo M, ZurzoloC(2013) The cell biology of prion-like spread of protein aggregates: Mechanisms and implication in neurodegeneration. Biochem J 452, 1-17.
29. Puzzo D, Arancio O (2013) Amyloid-peptide: Dr. Jekyll or Mr. Hyde J Alzheimers Dis 33(Suppl 1), S111-S120.
30. Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA (2007) Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J 26, 548-558. (Pubitemid 46160954)
31. Biasini E, Unterberger U, Solomon IH, Massignan T, Senatore A, Bian H, Voigtlaender T, Bowman FP, Bonetto V, Chiesa R, Luebke J, Toselli P, Harris DA (2013) A mutant prion protein sensitizes neurons to glutamate-induced excitotoxicity. J Neurosci 33, 2408-2418.
32. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279, 827-834. (Pubitemid 28106269)
33. Stewart RS, Harris DA (2003) Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection. J Biol Chem 278, 45960-45968. (Pubitemid 37432743)
34. Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (PrP(C)): Its physiological function and role in disease. Biochim Biophys Acta 1772, 629-644. (Pubitemid 46880208)
35. KudoW, Lee H-P, ZouW-Q,Wang X, Perry G, Zhu X, Smith MA, Petersen RB, Lee H (2012) Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. Hum Mol Genet 21, 1138-1144.
36. YouH, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, Engbers JDT, Lipton SA, Stys PK, Zamponi GW (2012) Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA 109, 1737-1742.
37. Caetano FA, Beraldo FH, Hajj GNM, Guimaraes AL, J̈urgensen S,Wasilewska-Sampaio AP, Hirata PHF, Souza I, Machado CF,Wong DY-L, De Felice FG, Ferreira ST, Prado VF, Rylett RJ, Martins VR, Prado MAM (2011) Amyloidbeta oligomers increase the localization of prion protein at the cell surface. J Neurochem 117, 538-553.
38. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754.
39. Caetano FA, Lopes MH, Hajj GNM, Machado CF, Pinto Arantes C, Magalh̃aes AC, Vieira MDPB, Aḿerico TA, Massensini AR, Priola SA, Vorberg I, Gomez MV, Linden R, Prado VF,Martins VR, Prado MAM (2008) Endocytosis of prion protein is required for ERK1/2 signaling induced by stress-inducible protein 1. J Neurosci 28, 6691-6702.
40. Taylor DR, Hooper NM (2007) The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J 402, 17-23.
41. Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, Lee KS, MagalhaesAC, Caetano FA, Mancini GL, Lopes MH, Americo TA, Magdesian MH, Ferguson SSG, Linden R, Prado MAM, Martins VR (2011) Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma 1 chain. FASEB J 25, 265-279.
42. Lewis V, Hooper NM (2011) The role of lipid rafts in prion protein biology. Front Biosci 16, 151-168.
43. Suzuki KGN, Fujiwara TK, Sanematsu F, Iino R, Edidin M, KusumiA(2007) GPI-anchored receptor clusters transiently recruit Lyn and G alpha for temporary cluster immobilization and Lyn activation: Single-molecule tracking study 1. J Cell Biol 177, 717-730. (Pubitemid 46799842)
44. Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF,Mac-Donald JF (2011) Fyn, a potential target for Alzheimer's disease. J Alzheimers Dis 27, 243-252.
45. Revett TJ, Baker GB, Jhamandas J, Kar S (2013) Glutamate system, amyloid peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38, 6-23.
46. Rial D, Piermartiri TC, Duarte FS, Tasca CI, Walz R, Prediger RD (2012) Overexpression of cellular prion protein (PrPC) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-beta (A (1-40)) administration in mice. Neuroscience 215, 79-89.
47. Hyeon JW, Kim SY, Park JS, Choi BY, Lee SM, Ju YR, An SSA, Kim C-K (2012) The association between prion proteins and Abeta(1-42) oligomers in cytotoxicity and apoptosis. Biochem Biophys Res Commun 424, 214-220.
48. Alier K, Ma L, Yang J, Westaway D, Jhamandas JH (2011) Ainhibition of ionic conductance in mouse basal forebrain neurons is dependent upon the cellular prion protein PrPC. J Neurosci 31, 16292-16297.
49. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, De Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
50. KesselsHW, Nguyen LN, Nabavi S, Malinow R (2010) The prion protein as a receptor for amyloid-beta. Nature 466, E3-E4.
51. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM (2010) Memory impairment in transgenic alzheimer mice requires cellular prion protein. J Neurosci 30, 6367-6374.
52. Cisse M, Sanchez PE, Kim DH, Ho K, Yu G-Q, Mucke L (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 31, 10427-10431.
53. Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM,Wisniewski T (2010) Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci 11, 130.
54. Westaway D, Jhamandas JH (2012) The P's and Q's of cellular PrP-Abeta interactions. Prion 6, 359-363.
55. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ, Hooper NM (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 104, 11062-11067. (Pubitemid 47175226)
56. Baumann MH, Kallij̈arvi J, Lankinen H, Soto C, Haltia M (2000) ApolipoproteinEincludes a binding site which is recognized by several amyloidogenic polypeptides. Biochem J 349, 77-84. (Pubitemid 30440167)
57. Gao C, Lei Y-J, Han J, Shi Q, Chen L, Guo Y, Gao Y-J, Chen J-M, Jiang H-Y, ZhouW, Dong X-P (2006) Recombinant neural protein PrP can bind with both recombinant and native apolipoprotein E in vitro. Acta Biochim Biophys Sin 38, 593-601. (Pubitemid 44395193)
58. Schmitt-Ulms G, Hansen K, Liu J, Cowdrey C, Yang J, DeArmond SJ, Cohen FE, Prusiner SB, BaldwinMA(2004) Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol 22, 724-731. (Pubitemid 38702829)
59. Canu N, Filesi I, Pristeŕa A, Ciotti MT, Biocca S (2011) Altered intracellular distribution of PrPC and impairment of proteasome activity in tau overexpressing cortical neurons. J Alzheimers Dis 27, 603-613.
60. Pflanzner T, Petsch B, Andre-Dohmen B, Mueller-Schiffmann A, Tschickardt S, Weggen S, Stitz L, Korth C, Pietrzik CU (2012) Cellular prion protein participates in amyloid-beta transcytosis across the blood-brain barrier. J Cereb Blood Flow Metab 32, 628-632.
61. Pflanzner T, JankoMC, Andŕe-Dohmen B, Reuss S,Weggen S, Roebroek AJM, Kuhlmann CRW, Pietrzik CU (2011) LRP1 mediates bidirectional transcytosis of amyloid-across the blood-brain barrier. Neurobiol Aging 32, 2323. e1-e11.
62. Kaiser DM, Acharya M, Leighton PLA, Wang H, Daude N,Wohlgemuth S, Shi B, Allison WT (2012) Amyloid beta precursor protein and prion protein have a conserved interaction affecting cell adhesion and CNS development. PLoS One 7, e51305.
63. Nilsberth C,Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, N̈aslund J, Lannfelt L (2001) The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4, 887-893. (Pubitemid 32801591)
64. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, ImagawaM, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008)Anewamyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63, 377-387. (Pubitemid 351499867)
65. Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, De Quervain DJ-F (2005) The prion gene is associated with human long-term memory. Hum Mol Genet 14, 2241-2246. (Pubitemid 41418023)
66. Breitling LP, M̈uller H, Stegmaier C, Kliegel M, Brenner H (2012) Association of prion protein with cognitive functioning in humans. Exp Gerontol 47, 919-924.
67. He J, Li X, Yang J, Huang J, Fu X, Zhang Y, Fan H (2013) The association between the methionine/valine (M/V) polymorphism (rs1799990) in the PRNP gene and the risk of Alzheimer disease: An update by meta-analysis. J Neurol Sci 326, 89-95.
68. Calero O, Bullido MJ, Clariḿon J, Frank-Garća A, Mart́nez-Mart́n P, Lléo A, Rey MJ, Ŕabano A, Blesa R, Ǵomez-Isla T, Valdivieso F, De Pedro-Cuesta J, Ferrer I, Calero M (2011) Genetic cross-interaction between APOE and PRNP in sporadic Alzheimer's and Creutzfeldt-Jakob diseases. PloS one 6, e22090.
69. Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, Van Duijn CM, Cruts M, Van Broeckhoven C, Martin JJ, Cras P (2001) Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett 313, 69-72. (Pubitemid 32973897)
70. Bernardi L, Anfossi M, Gallo M, Geracitano S, Cola R, Puccio G, Curcio SAM, Frangipane F, Mirabelli M, Clodomiro A, Di Lorenzo R, Smirne N, Maletta R, Iapaolo D, BruniAC (2011) PSEN1 and PRNP gene mutations: Co-occurrence makes onset very early in a family with FTD phenotype. J Alzheimers Dis 24, 415-419.
71. Giovagnoli AR, Di Fede G, Aresi A, Reati F, Rossi G, Tagliavini F (2008) Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family. Neurol Sci 29, 405-410.
72. Mauro C, Giaccone G, Piscosquito G, Lavorgna A, Nigro M, Di Fede G, Leonardi A, Coppola C, Formisano S, Tagliavini F, Cotrufo R, Puoti G (2008) A novel insertional mutation in the prion protein gene: Clinical and bio-molecular findings. J Neurol Neurosurg Psychiatry 79, 1395-1398.
73. Clerici F, Elia A, Girotti F, Contri P, Mariani C, Tagliavini F, Di Fede G (2008) Atypical presentation of Creutzfeldt-Jakob disease: The first Italian case associated with E196K mutation in the PRNP gene. Neurol Sci 275, 145-147.
74. Premi E, Pilotto A, Alberici A, Papetti A, Archetti S, Seripa D, Daniele A, Masullo C, Garibotto V, Paghera B, Caobelli F, Padovani A, Borroni B (2012) FOXP2, APOE, and PRNP: New modulators in primary progressive aphasia. J Alzheimers Dis 28, 941-950.
75. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30, 4528-4535.
76. Saijo E, Scheff SW, Telling GC (2011) Unaltered prion protein expression in Alzheimer disease patients. Prion 5, 110-117.
77. Velayos JL, Irujo A, Cuadrado-Tejedor M, Paternain B, Moleres FJ, Ferrer V (2009) The cellular prion protein and its role in Alzheimer disease. Prion 3, 110-117.
78. Whitehouse IJ, Jackson C, Turner AJ, Hooper NM (2010) Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. J Alzheimers Dis 22, 1023-1031.
79. Pankiewicz J, Prelli F, Sy M-S, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M,Wisniewski T (2006) Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 23, 2635-2647. (Pubitemid 43801455)
80. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83. (Pubitemid 36323299)
81. Antonyuk SV, Trevitt CR, Strange RW, Jackson GS, Sangar D, Batchelor M, Cooper S, Fraser C, Jones S, Georgiou T, Khalili-Shirazi A, Clarke AR, Hasnain SS, Collinge J (2009) Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci USA 106, 2554-2558.
82. Guillot-Sestier M-V, Sunyach C, Druon C, Scarzello S, Checler F (2009) The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem 284, 35973-35986.
83. Wehling M (2009) Assessing the translatability of drug projects: What needs to be scored to predict success Nat Rev Drug Discov 8, 541-546.
84. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
85. Mullard A (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 11, 657-660.
86. Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 33(Suppl 1), S67-S78.
87. Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153, 707-720.
88. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LBH, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrj̈anheikki J, Fillit HM (2011) Accelerating drug discovery for Alzheimer's disease: Best practices for preclinical animal studies. Alzheimers Res Ther 3, 28.
89. Sabbagh JJ, Kinney JW, Cummings JL (2013) Animal systems in the development of treatments for Alzheimer's disease: Challenges, methods, and implications. Neurobiol Aging 34, 169-183.
90. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munaf̀o MR (2013) Power failure: Why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14, 365-376.
91. Wang-Dietrich L, Funke SA,K̈uhbach K,Wang K, Besmehn A, Willbold S, Cinar Y, Bannach O, Birkmann E, Willbold D (2013) The amyloid oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 34, 985-994.
92. Santos AN, Ewers M, Minthon L, Simm A, Silber R-E, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29, 171-176.
93. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N,Weiss K,Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919. (Pubitemid 30644751)
94. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS,Watts RJ (2013) Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 5, 183ra57.
95. Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, KleinWL,ChauhanNB(2013) Brain transit and ameliorative effects of intranasally delivered anti-amyloid-oligomer antibody in 5XFAD mice. J Alzheimers Dis 35, 777-788.
96. Aguzzi A, Baumann F, Bremer J (2008) The prion's elusive reason for being. Annu Rev Neurosci 31, 439-477.
97. Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, Steele AD, ToykaKV,Nave K-A,Weis J, Aguzzi A (2010) Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 13, 310-318.
98. Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J, Kato S, Ishida I, Soto C, Robl JM, Kuroiwa Y (2007) Production of cattle lacking prion protein. Nat Biotechnol 25, 132-138. (Pubitemid 46087911)
99. Benestad SL, Austbø, L, Tranulis MA, Espenes A, Olsaker I Healthy goats naturally devoid of prion protein. Vet Res 43 87.
100. Si K, Choi Y-B, White-Grindley E, Majumdar A, Kandel ER (2010) Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 140, 421-435.
101. Solforosi L, Criado JR, McGavern DB, Wirz S, Śanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B,Williamson RA (2004) Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514-1516. (Pubitemid 38314420)
102. Lefebvre-Roque M, Kremmer E, Gilch S, Zou W-Q, F́eraudet C, Gilles CM, Sal̀es N, Grassi J, Gambetti P, Baron T, Scḧatzl H, Lasḿezas CI. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 1, 198-206.
103. Kl̈ohn P-C, Farmer M, Linehan JM, O'Malley C, Fernandez de Marco M, Taylor W, Farrow M, Khalili-Shirazi A, Brandner S, Collinge J (2012) PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science 335, 52.
104. Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104, 9741-9746. (Pubitemid 47175337)
105. Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV, Soto C (2012) Protein misfolding cyclic amplification of infectious prions. Nat Protoc 7, 1397-1409.
106. Kozauer N, Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368, 1169-1171.
107. Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457. (Pubitemid 34454251)